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Conference Report
CASE ONE
Dr Lam Man Fai from Queen Mary Hospital discussed 
the management of late-onset antibody-mediated re-
jection (ABMR) in a female who had received a 
living-related renal transplant 23 years earlier. Her 
serum Cr had gradually increased to 220 μmol/L, with 
proteinuria 0.5 g/day, while she was being prescribed 
4 mg prednisolone and 50 mg azathioprine daily. She 
refused an allograft biopsy, prompting the additional 
prescription of empirical sirolimus (rapamycin) and an 
angiotensin converting enzyme (ACE) inhibitor to con-
trol proteinuria. After 10 months, her Cr levels had in-
creased to 270 μmol/L, with proteinuria 1.09 g/day. The 
patient still refused an allograft biopsy and was put on 
4 mg prednisolone and 1 mg sirolimus daily (level at 
6.7) plus an ACE inhibitor and angiotensin receptor 
blocker (ARB). The Cr level continued to creep up, and 
reached 350 μmol/L before she eventually agreed to 
a biopsy. The biopsy showed chronic allograft glom-
erulopathy, peritubular capillaritis involving < 50% 
of capillaries, diffuse C4d deposition in the peritubular 
and glomerular capillaries (Figure 1), and moderate 
interstitial fibrosis and tubular atrophy, leading to a 
diagnosis of chronic active ABMR with chronic allograft 
glomerulopathy.
In the discussion of the diagnostic criteria for 
AMBR, the majority (39%) of delegates agreed that the 
diagnostic criteria for ABMR are a composite of mor-
phologic evidence of peritubular and glomerular capil-
lary damage, C4d-positive peritubular capillaries and 
the presence of circulating antibodies to donor HLA 
(Figure 2).
Dr MK Chan: Two out of three criteria should be ade-
quate to confirm ABMR, given limited resources.
Prof Chadban: Detection of circulating donor-specific 
antibodies supports a diagnosis of ABMR over other 
differentials, such as recurrent glomerulonephritis.
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tal, served as moderator. Professor Chadban then discussed various management options in immunosuppression 
within the context of the four local case reports. [Hong Kong J Nephrol 2009;11(1):20–9]
Figure 1. Biopsy showed diffuse C4d in the peritubular and 
glomerular capillaries.
The opinions expressed in this workshop are those of the speakers and do not represent the official views of the Hong Kong 
Society of Nephrology, the Hong Kong Society of Transplantation or Elsevier.
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While discussing donor-specific antibodies, half of the 
delegates agreed that they could be eluted from patient 
serum (Figure 3).
Prof Chadban: Theoretically, you should be able to 
elute donor-specific antibodies from both serum and 
allograft tissue, but in clinical practice we would never 
seek to elute antibodies from allograft tissue.
The delegates were then asked what treatment they 
would suggest and 33% of participants chose option A 
(Figure 4).
Dr MK Chan: I would probably choose none of these. 
I would actually prefer to use plasmapheresis plus pulse 
steroid therapy. Plasmapheresis plus intravenous im-
munoglobulin is far too expensive.
The patient was treated with plasmapheresis + IVIG, 
tacrolimus and mycophenolate mofetil (MMF). She was 
found to be positive for anti-DR53, which was not pres-
ent in her donor father and it was unsure if it was related 
to an earlier pregnancy. The graft failed and long-term 
peritoneal dialysis (PD) was required.
CASE TWO
Dr Cheuk Au from Princess Margaret Hospital (PMH) 
presented the case of a 39-year-old male patient with 
creeping Cr levels who refused a renal biopsy. He had 
received a cadaveric renal transplant for chronic renal 
failure in China in September 2004. Immunosuppres-
sants being taken by the patient included cyclosporine 
A (CsA), MMF and prednisolone. The patient’s best Cr 
level was 120 μmol/L, which was noted upon his dis-
charge from the hospital and subsequent return to Hong 
Kong. He was admitted to PMH in October 2004 with 
fever and urinary frequency. On arrival, his urinary WBC 
count was > 100, his serum Cr level was 178 μmol/L, 
and no hydronephrosis of the graft kidney was seen with 
ultrasonography. He was given antibiotics for a urinary 
tract infection (UTI) and the fever responded, but his 
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Figure 2. What are the diagnostic criteria for antibody-mediated 
rejection?
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Figure 3. Donor-specific antibodies could be eluted from patient 
serum, allograft tissue or both.
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Figure 4. What would you suggest for the treatment?
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Cr levels rapidly increased to 263 μmol/L. A graft renal 
biopsy showed histologic features of acute tubular 
necrosis (ATN) and acute CsA toxicity (Figure 5).
He was treated with a reduced dose of CsA and his 
Cr levels had decreased to 189 μmol/L upon his dis-
charge in November 2004. However, in September 2005 
he developed Pneumocystis carinii pneumonia (PCP) 
infection, which responded to i.v. Septrin and long-term 
prophylaxis was started. From November 2004 to 
October 2005, his serum Cr level fluctuated between 
180 and 260 μmol/L (mean Cr clearance, 38.6 mL/min), 
while proteinuria increased steadily from 0.1 to 0.6 g/
day. While discussing what advice to give the patient at 
this point, most respondents (70%) opted to recommend 
a 2nd biopsy (Figure 6).
Dr Ignatius Cheng: I agree that a second biopsy would 
be helpful.
The team then advised the patient to have a 2nd biopsy, 
but he refused and immunosuppressive options were 
discussed instead. When asked which immunosuppres-
sive regime they would use, 87% of the delegates recom-
mended changing to mammalian target of rapamycin 
(mTOR) inhibitors with calcineurin inhibitor (CNI) 
withdrawal (Figure 7).
Dr Ignatius Cheng: I think that without renal biopsy, 
it is obviously guess work since cyclosporine toxicity 
may be present, even with what we call the therapeutic 
dose of cyclosporine, and my main worry is the patient 
may have some sort of chronic rejection. I entirely agree 
to either reduce the cyclosporine dose or even better—
change to mTOR.
The option of CNI withdrawal was discussed, with 
which the patient agreed. He was started on siroli-
mus + MMF + prednisolone in October 2005, with CsA 
gradually reduced over 2 weeks. The only side effects 
experienced by the patient were oral ulcers, which re-
solved with the dose reduction. His lipid and hemoglobin 
levels were well maintained, and renal function im-
proved gradually, with the latest Cr levels of 127 μmol/L 
and mean Cr clearance of 80 mL/min over the past year 
(Figure 8). Moreover, no proteinuria was detected in the 
last three specimens. Therefore, renal function improved 
after CNI withdrawal and introduction of sirolimus/
MMF/steroid as the maintenance regimen.
Figure 5. Graft renal biopsy showed histologic features of ATN and 
acute CsA toxicity. 0
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Figure 6. Would you advise the patient to have a second allograft 
biopsy?
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Figure 7.  What immunosuppressive regime would you 
recommend?
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Dr Ignatius Cheng: It is surprising how well he did by 
changing from cyclosporine to mTOR. Perhaps the CNI 
toxicity in this patient was not too severe, but what is 
amazing is the fact that he recovered his creatinine after 
this had been elevated for quite some time.
Prof Chadban: I would agree with you absolutely and 
I suspect that it is the withdrawal of the CNI rather than 
the sirolimus effect.
Dr MK Chan: It is not surprising that his renal function 
improved on reducing the CNI. However, if I were 
managing this patient, the only thing I would probably 
do differently is I would not use the triple therapy, given 
the fact that this patient has had a PCP infection before. 
I don’t think the MMF in this particular situation has 
added anything to sirolimus. I would not use MMF in 
CNI toxicity; I would rather use sirolimus plus steroid 
instead.
Prof Philip Li: CNI withdrawal may have been respon-
sible for most of the renal function improvement, while 
fluctuating serum Cr levels may also signify a hemody-
namic disturbance, rather than tubular functional dys-
function, suggesting cyclosporine toxicity in its acute 
form.
CASE THREE
Dr Bonnie Kwan from Prince of Wales Hospital reported 
a case of new-onset diabetes mellitus post-transplant 
(NODAT). The patient presented in April 2003 after 
receiving his second cadaveric renal transplant in China 
3 months previously. He had a history of living-related 
renal transplant in 1986, which developed graft renal 
cell carcinoma (RCC) and was removed in July 2000. 
The patient received hemodialysis until his most recent 
transplant in January 2003. The best postoperative serum 
Cr level was 103 μmol/L. At presentation, his immuno-
suppressant regimen included prednisolone, tacrolimus 
and MMF. Urine multistix showed glycosuria and 
albuminuria. He had mildly raised serum bilirubin 
and liver enzymes. When asked which immunosuppres-
sive regime they would recommend, most respondents 
(36%) opted to change to a CsA/MMF/steroid regimen 
(Figure 9).
Dr KF Chau: The history of RCC affects the choice of 
immunosuppressants, for which I would choose an 
mTOR-based regime. Regarding the newly developed 
DM, both steroids and FK are bad. FK is said to be worse 
than CsA, but for Hong Kong Chinese, the difference 
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Figure 8. Creatinine versus time.
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Figure 9.  What immunosuppressive regime would you 
recommend?
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is not as great as in Caucasians, probably because we 
use a much lower dose of FK. In this particular case, 
I would choose CsA + mTOR.
Dr BY Choy: Because this is the second transplant, 
I would prefer to use a more potent immunosuppressive 
regime to prevent rejection. With the presence of gly-
cosuria, DM has to be excluded. I don’t know what 
the patient’s latest renal function is, but there may still 
be grounds for reduction of the doses of steroid and FK. 
I would request more information on his FK level and 
steroid dose to see if further dose reductions are pos-
sible. If the blood glucose is high, I would use insulin 
or other oral hypoglycemic agents to control the blood 
sugar.
At the time of treatment, a regimen comprising tacroli-
mus, azathioprine and prednisolone was chosen. Sub-
sequent investigations confirmed NODAT, with an 
HbA1c of 8.3% and fasting glucose level of 14 mmol/L. 
Glucose control remained suboptimal despite com-
mencement of gliclazide, so insulin was added, a move 
agreed upon by most respondents (33%) (Figure 10).
Dr KF Chau: I would add insulin for better control of 
the diabetes. I would also tail down steroid and FK or 
change to other immunosuppressants.
Dr BY Choy: Switching to insulin is important for 
control of the diabetes. I also notice that he has liver 
function impairment, in which case, azathioprine 
should probably be stopped as it may affect the liver 
function.
Further elevations of bilirubin and liver enzymes in May 
2003 prompted the discontinuation of azathioprine, 
which elicited only transient improvements in liver 
enzyme levels. The patient was maintained on predni-
solone 10 mg/day and tacrolimus 0.5 mg/day (trough 
level, 12.9 μg/L). Despite negative anti-hepatitis C virus 
(HCV) antibody, the patient was positive for HCV RNA. 
Ribavirin and pegylated interferon (PEG-INF) was 
prescribed. The serum Cr level was stable at 130–150 
μmol/L, but worsening of anemia (Hb, 7.2 g/dL) and 
leukopenia (WBC, 1.8 × 109/L) ensued. In discussing 
what to do next, 48% opted to discontinue ribavirin ± 
PEG-INF (Figure 11).
Dr KF Chau: I agree with the majority.
Dr BY Choy: It is a very courageous decision to use 
interferon in transplant patients, as there is always risk 
of rejection in this group of patients.
Anemia and leukopenia improved after the discontinu-
ation of ribavirin in March 2004, while the liver enzymes 
slowly normalized with the use of PEG-INF until 
September 2004. With further titration of medications, 
the latest laboratory results showed serum Cr levels of 
200 μmol/L while on prednisolone 5 mg/day and tac-
rolimus 1 mg/day (trough level, 5.6 μg/L), fair glycemic 
control (HbA1c, 6.5%) and normal liver enzymes. When 
asked to consider a similar scenario whereby a patient 
developed NODAT and hepatitis B after his first trans-
plant, most delegates (46%) chose an immunosuppres-
sive regimen comprising CsA/MMF/steroid, with 31% 
opting for an mTOR-based regimen (Figure 12).
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Figure 10. What would you do next?
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Figure 11. What would you do next?
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Dr KF Chau: The choice is very reasonable. Everyone 
is trying to avoid FK, because of the higher chance of 
diabetes. I would also try to minimize the dose of 
steroids. mTOR is too weak when used alone with 
CsA, but the choice may also depend on the availability 
of drugs and the financial implications.
Dr BY Choy: For the first renal transplant, I would not 
consider an extremely potent immunosuppressive regime. 
With development of NODAT, I would consider a steroid-
free regime. PSI-based regime may also be a choice.
Prof Chadban: Little is known about mTORs in hepa-
titis; however, emerging evidence has linked sirolimus 
usage with an increased risk of new-onset DM, particu-
larly when used with a CNI.
Dr MK Chan: After the interferon was given, what 
happened to the HCV RNA?
Dr Bonnie Kwan: The RNA came down, but it was still 
detectable, and after that his liver enzymes normalized.
Dr MK Chan: I have very limited experience in using 
interferon in HCV-positive transplant patients. I’ve 
treated three such patients with interferon: one of the 
patients rejected, so there is a chance of rejection in this 
situation. But what worries me is RCC and the fact that 
you had this suspicious-looking lesion on the kidney. If 
you had the chance, you should perhaps have performed 
a nephrectomy before the patient had his second kidney 
transplant. As for post-transplant diabetes, it is a very 
common situation that we would expect to encounter. 
The best treatment is to get the patient off steroids. 
Switching to an mTOR would probably not improve the 
diabetes very much, but choosing a steroid-free regimen 
is the best treatment.
Dr Ignatius Cheng: I agree with you about the steroids. 
The other point I want to make concerns hepatitis C and 
the use of ribavirin and interferon in kidney transplant 
patients. I and my colleagues at Queen Mary Hospital 
have treated six patients with HCV infection with 
pegulated interferon and ribavirin. All completed the 
course of treatment without rejection. The doses of 
interferon and ribavirin did need to be adjusted. As 
ribavirin also has an immunomodulatory effect, its use 
together with interferon may have counteracted the 
effects of interferon in inducing graft rejection.
CASE FOUR
Dr John Y.H. Chan from Queen Elizabeth Hospital 
presented the case of a 42-year-old female with recurrent 
bladder cancer. The patient, who was known to have 
thalassemia and a history of taking herbal medications, 
had originally presented with anemia and impaired renal 
function (Cr, 200 μmol/L) in 1998. A renal biopsy at the 
time showed diffuse glomerulosclerosis of unknown 
etiology. Renal function gradually deteriorated until she 
reached end-stage renal failure in April 2000. The pa-
tient received temporary hemodialysis until May 2000, 
when she received a cadaveric transplantation in China. 
She received maintenance immunosuppressive therapy 
with CsA/MMF/steroid. Postoperatively, she suffered 
from pulmonary edema requiring temporary hemodi-
alysis. Renal biopsy showed acute rejection. After 3 
days of pulse methylprednisolone, her renal function 
recovered and the serum Cr level at discharge was 130 
μmol/L. In September 2000, due to severe hirsutism, 
treatment was switched to tacrolimus 4 mg o.m./3 mg 
p.m., MMF 750 mg, and prednisolone 10 mg/day. The 
patient developed hematuria in December 2000. At that 
time, she was receiving tacrolimus 2 mg b.i.d., MMF 
500 mg b.i.d., and prednisolone 7.5 mg/day. Cystoscopy 
revealed a papillary growth, which was identified as a 
grade 2–3 papillary transitional cell carcinoma (TCC) 
on biopsy, prompting transurethral resection of bladder 
tumor (TURBT) in January 2001. When asked what to 
do at this point, 87% of delegates opted to change to an 
mTOR-based regime (Figure 13).
Prof Philip Li: In the early days, post-transplant malig-
nancy, especially with very high dose CsA, could have 
been related to the immunosuppressants that were used. 
It is not sure if there is any overwhelming evidence 
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Figure 12. What immunosuppressive regime would you 
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suggesting that putting the patient on a steroid-free 
regime can prevent post-transplant bladder cancer.
The dosage of tacrolimus was further reduced to 2 mg 
o.m./1.5 mg p.m. and she was followed-up with 3-
monthly cystoscopic surveillance. In May 2001, cystos-
copy showed multiple recurrences, prompting TURBT 
with local chemotherapy. Cystoscopy in June was 
negative and her renal function was stable (Cr, 110 
μmol/L). Asked what to do next, 54% would reduce the 
CNI dose, while 32% would discontinue the MMF, 
which is what Dr Chan did, since mTOR was unavail-
able at the time (Figure 14).
Prof Philip Li: Reducing CNI would be my first choice, 
especially reducing CNI early if tacrolimus is used. In a 
patient with bladder cancer, the combination of tacroli-
mus with high-dose MMF is definitely not desirable.
In August 2001, a repeat cystoscopy led to a diagnosis 
of recurrent TCC involving the left native ureter. Left 
nephroureterectomy was performed in September and 
the patient was discharged on prednisolone 7.5 mg/day 
plus tacrolimus 2 mg o.m./1.5 mg p.m. The finding of 
atypical cells in a urinary cytology examination in 
October that year prompted an abdominal CT, which 
revealed gross right hydronephrosis and hydroureter 
with an intraluminal density in the right native ureter 
suggestive of ureteral obstruction of the right native 
kidney. Right nephroureterectomy was performed and 
recurrent grade 3 papillary TCC was diagnosed. This was 
treated with TURBT, but was followed by four more 
recurrences necessitating TURBT from November 2004 
through September 2005, by which time mTOR was 
available. While discussing which immunosuppressive 
regime they would recommend, 75% of delegates chose 
to change to an mTOR-based regimen (Figure 15).
Prof Chadban: At some stage, she may elect to undergo 
complete withdrawal of immune suppression, where-
upon her life will be different.
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Figure 13. What would you do at this time, in view of the post-
transplant bladder cancer?
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Figure 14. What would you do at this time?
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Prof Philip Li: I agree with that point, but at this stage 
she was seemingly doing very well, with the local treat-
ment appearing to be successful each time. But the 
patient should be made aware that at some time she 
might deteriorate because of the malignancy. However, 
even if we withdraw all immunosuppressants, the can-
cer may still recur.
This option was discussed with the patient, who pre-
ferred to stay on the original regimen. Cystoscopy re-
mained negative with normal renal function until a 9th 
grade 3 papillary TCC recurrence was diagnosed in 
September 2007, at which time the patient agreed to 
change to mTOR plus prednisolone. When asked how 
they would stop CNI treatment, 67% of participants 
chose the gradual approach (Figure 16).
Prof Philip Li: This patient has had 10 cancer recur-
rences over 9 years, so there should be very little reason 
for an abrupt cessation of CNI.
Tacrolimus was removed from the regime and the patient 
was started on sirolimus 3 mg/day plus prednisolone 
5 mg/day. However, she had a 10th relapse in June 2008 
and is currently receiving ongoing treatment.
Dr Ignatius Cheng: Firstly, it is not clear if the repeated 
local recurrences are related to the herbal medicine that 
the patient has been taking. Secondly, it is known that 
CNI will transform cells no matter what kind of dose is 
being used. It may be important to withdraw CNI.
Dr MK Chan: I think there is the possibility that some 
of this may be related to the herbal medicine. I actually 
suspect that the original source of the transitional cell 
carcinoma is related to herbal toxins, as has been shown 
in animals with transitional cell carcinomas. We cannot 
exclude lead poisoning either. We have actually found 
increased lead excretion believed to be related to herbal 
medicines in patients with end-stage renal failure.
Prof Philip Li: I think that it might be worth finding 
out what the patient has been taking over time. The 
patient may have been taking things that you are not 
aware of since her kidney was removed 4–5 years ago, 
and may still be continuing to take these preparations.
Dr KF Chau: In Taiwan, there is a high incidence of 
post-transplant CA bladder because of intake of herbs. 
This particular patient was taking herbs before her renal 
failure. If this habit persists, it may account for the re-
current CA bladder.
·······································
Professor S. Chadban presented his views on the four 
case reports and discussed various management options 
in immunosuppression. The main lessons from the cases 
concern the key causes of graft loss: mortality and 
chronic allograft nephropathy (CAN). Case One showed 
that acute ABMR remains a problem, while Case Two 
underlined the importance of tissue biopsy in guiding 
prognosis and appropriate therapy for CAN, particularly 
if a switch from CNI to mTOR is considered. Case Three 
looked at NODAT and highlighted its importance, in 
particular regarding mortality, while Case Four regarded 
recurrent post-transplant cancer, a major problem 
for which the mTORs offer hope for prevention and 
management.
REJECTION
Many different agents are available for immunosuppres-
sion to prevent acute graft rejection, so treatment can 
be tailored to individuals. Drug intolerance is relatively 
common, with 20–49% of subjects withdrawing prema-
turely from therapy in one series [1], so access to several 
agents is important. New immunosuppressive treatments 
have led to steady reductions in graft loss due to acute 
rejection and thereby improvements in 1-year patient 
survival of 95% to 100%, and 90–95% kidney graft 
survival rates since 1990 [2]. However, acute rejection 
(AR) remains problematic, affecting 25% of renal graft 
recipients in 2002 in Australia, although early diagnosis 
and treatment enabled 95% 1-year graft survival [3]. 
When AR incidence is categorized according to type, 
in Australia the majority is cellular rejection and a mi-
nority of cases show a glomerular (18%) or vascular 
(32%) component [3]. Vascular rejection has a signifi-
cant negative impact on graft survival beyond the first 
year post-transplantation, compared with that seen in 
transplant recipients with no rejection or of a non-
vascular origin [3]. Graft survival is also reduced over 
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Figure 16. How would you stop CNI treatment?
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time if patients have a poor response to treatment of 
the first rejection episode versus those who have a 
good response [3]. In addition, the type of AR also af-
fects renal function 1 year post-transplant, with signifi-
cantly higher serum Cr levels seen in vascular or mixed 
rejection [3].
Long-term outcomes remain a key concern. Graft 
failure rates beyond the first year after transplantation 
remain at 4–6% per annum, despite advances in im-
munosuppression. Whereas graft loss due to acute rejec-
tion is infrequent beyond year 1, losses due to death 
with functioning graft, CAN and recurrent disease in-
crease over time [4]. The contribution of CNI nephro-
toxicity to CAN has been demonstrated and the 
importance of CNI monitoring and minimization in 
selected cases is evident [5].
DIABETES
Cardiovascular disease (CVD) is the leading cause of 
death in patients with a functioning graft, accounting 
for 47.6% of mortality in a series of 534 deceased-donor 
kidney transplants [6]. The main risk factor for cardio-
vascular events after kidney transplantation is DM, 
which was associated with a relative risk (RR) of 5.4 
for ischemic heart disease events occurring in women 
and 2.78 for men > 1 year after kidney transplantation 
in a US study (n = 1124). RRs for hypercholesterolemia, 
hypertension and smoking were 2.07/2.39, 1.63/1.19 
and 1.82/1.95, respectively [7]. A recent US registry 
data analysis of  > 27,000 primary kidney transplant 
patients with a minimum follow-up of 1 year demon-
strated that the key impact of NODAT is on death with 
a functioning graft [8]. In a Norwegian study of kidney 
transplant recipients, NODAT was associated with a 
twofold increased risk of death (HR, 2.11; 95% CI, 
1.09–4.09; p = 0.026) and a threefold increased risk of 
major cardiac events (HR, 3.27; 95% CI, 1.22–8.80; 
p = 0.019), versus non-diabetic recipients [9]. Mecha-
nisms of NODAT include insulin resistance due to 
treatment with steroids, CNIs and mTOR, inflammation 
due to cytomegalovirus (CMV) infection, and obesity 
and inactivity, together with insulin deficiency due to 
treatment with tacrolimus and, to a lesser extent, CsA 
and mTOR, older age and enhanced insulin clearance 
post-transplant. In a US registry data analysis, sirolimus 
was found to be associated with NODAT independently 
of CNI [10], and in the study by Ekberg et al, the inci-
dence of NODAT at month 12 post-transplant was 
highest with low-dose tacrolimus (10.6%; n = 403) 
compared with low-dose sirolimus (7.8%; n = 380), and 
standard-dose (6.4%; n = 384) and low-dose (4.7%; 
n = 408) Neoral (CsA) [1]. In a prospective, controlled 
study of cyclosporine versus tacrolimus with the primary 
outcome of NODAT or impaired fasting glucose, a 
significantly lower incidence was seen with CsA [11]. 
Equal degrees of insulin resistance were induced by 
cyclosporine and tacrolimus, although insulin deficiency 
was significantly greater with tacrolimus. These findings 
are consistent with previous studies of the impact of 
tacrolimus and cyclosporine on pancreatic function in 
vitro and in vivo [12,13].
CANCER
Cancer represents a major problem for transplant 
recipients. Data from the ANZDATA Registry of 
Australia and New Zealand between 1963 and 2002 
show that the cumulative risk of any cancer increases 
to 80% 30 years post-transplant, with that for non-skin 
cancer being 40%, versus < 10% among the age-matched 
general population. Therefore, the recent advent of the 
mTORs, sirolimus and everolimus (RAD-100), is timely, 
since they have been shown to have antiproliferative 
action in RCC [14]. In a study in murine models, siroli-
mus 5 mg/kg/day significantly impaired recovery of 
lymphatic flow across surgical incisions resulting in 
prolonged edema versus controls (p = 0.004) [15]. In-
growth of lymphatic vessels into Matrigel plugs was 
significantly decreased by sirolimus (p = 0.002 vs. con-
trols) [15]. Moreover, sirolimus 20 ng/mL significantly 
inhibited vascular endothelial growth factor-C (VEGF-
C)-driven proliferation and migration of isolated human 
lymphatic endothelial cells in vitro (p < 0.05 vs. controls) 
[15]. In addition, mTOR inhibition impaired down-
stream signaling of VEGF-A and VEGF-C signaling via 
mTOR to the p70S6 kinase, as shown by Western blot 
analysis [15]. These antilymphangiogenic properties of 
sirolimus and everolimus may have therapeutic value 
in the prevention and treatment of transplant-related 
cancer.
CONCLUSION
ABMR remains difficult to manage. Care must be taken 
to obtain a correct diagnosis and biopsy is important in 
this but also in guiding prognosis and therapy. NODAT 
is a key contributor to death in patients with a function-
ing graft. New mTOR inhibitors are promising in the 
prevention and management of cancer in kidney trans-
plant recipients.
Dr MF Lam: Regarding drug levels of mTORs, you say 
based on the clinical trials the patients were found to 
have a lower incidence of cancer when they are put 
on mTORs when the drug level is probably about 
50–70 ng/mL. But now you are using sirolimus with a 
drug level of 6 or < 10 ng/mL. Do you have any comment 
on this?
Hong Kong J Nephrol • April 2009 • Vol 11 • No 1 29
 Treatment options for immunosuppression
Prof Chadban: I think there are two concepts that we 
need to be clear about. The first is that when giving an 
mTOR-based regime, we will expect to see less cancer 
than on a CNI-based regimen, however, the rate will 
still exceed that seen in the general (non-transplant) 
population. We are not using these drugs to lower the 
incidence of cancer, but because they are associated 
with less cancer than the CNIs. In that context, we 
generally aim for target levels of about 5–8 ng/mL dur-
ing the maintenance phase. The second scenario is a 
switch to mTOR to enhance treatment of a cancer in a 
transplanted patient. In existing studies, particularly 
with the renal cell carcinoma data, the doses used are 
10-fold what we are using in clinical transplantation. 
Nevertheless, there are also emerging data which sug-
gest that doses similar to those we use in kidney trans-
plant patients may work as an adjunct to chemotherapy 
or radiotherapy by increasing cell kill/promoting apop-
tosis. This may be a very useful therapeutic strategy. 
However, more data is required.
Dr MK Chan: In patients who have a tumor of a 
functioning transplant, the consensus is to change 
CNI to either sirolimus or everolimus. As you pointed 
out, in that sort of situation, the benefit for doing this is 
the discontinuation of CNI rather than the introduction 
of sirolimus or everolimus. However, it seems to 
me that the mTOR group of drugs has its antiprolifera-
tive properties; one would like to use them against 
specific groups of tumors like carcinoma of epithelial 
cell tumors. Is there any reported evidence for this 
indication?
Prof Chadban: Probably the best is for Kaposi’s sar-
coma, a tumor we seldom see. There was an NEJM 
report and some early reports from Spain showing that 
the mTORs have a specific ability against Kaposi’s 
sarcoma post-transplant: a case series of 10–18 patients 
with Kaposi’s sarcoma were switched from CNI-based 
therapy to mTOR at conventional levels of 10–15, and 
enjoyed complete regression of the tumor. However, the 
effect may not be durable as tumors can mutate to be-
come less responsive over time.
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